Portrait of group of women
getty
For almost ten years, millions of women have faced a diagnosis of polycystic ovary syndrome, a term that has hindered both prompt diagnosis and effective treatment. Recently, an initiative by the medical community and those affected has addressed this misnaming issue.
On May 12, 2026, The Lancet published a significant global consensus that rebranded the condition as polyendocrine metabolic ovarian syndrome. This new terminology was crafted through a unique collaboration involving 56 academic, clinical, and patient organizations, with feedback from over 14,300 individuals worldwide. Experts aimed to ensure that each term in the new name precisely reflects the wide range of symptoms and systems implicated in the condition.
This development represents more than a simple renaming; it signifies a shift toward a deeper understanding of the diagnosis’s complex nature.
Shruthi Mahalingaiah
Shruthi Mahalingaiah
“It acknowledges the complex multi-organ system aspects of the condition,” states Dr. Shruthi Mahalingaiah from the Division of Reproductive Endocrinology and Infertility at Massachusetts General Hospital. The decision’s impact is notable, as the condition affects up to 10% of women in their reproductive years. “The new name, PMOS, enhances the patient experience by improving education and long-term health management for prevention and risk reduction.”
What Was Wrong With The Name ‘PCOS’?
The diagnostic criteria for PCOS focus on three primary markers: abnormal ovulation, excess androgens, and pelvic ultrasound results. However, diagnosing the condition has proven difficult.
A 2020 review in Therapeutic Advances in Reproductive Health detailed the diagnostic controversies in detail. Over the years, the criteria have evolved from NIH guidelines in 1990, to the Rotterdam criteria in 2003, and the Androgen Excess Society criteria in 2006. This evolution means that a patient might be diagnosed under one framework but overlooked under another.
Hormone testing, a crucial diagnostic tool, lacks standardization, with reference ranges differing across labs, and most assays originally designed for male hormone levels. Ultrasound criteria for identifying polycystic ovaries have changed, with thresholds shifting from 10 to 12 to 19 or more follicles, depending on the period and technology used.
In adolescents, irregular cycles and multifollicular ovaries often represent normal puberty, complicating the differentiation between normal hormonal development and early disease.
What PMOS Gets Right
The term “polyendocrine” reflects the condition’s basis in various interacting hormonal pathways, such as insulin, androgens, and neuroendocrine signals. “Metabolic” highlights the long-known issues of insulin resistance, weight fluctuations, and increased cardiovascular risk as key features. “Ovarian” maintains the reproductive aspect, addressing irregular cycles, ovulation disruption, and fertility issues, while de-emphasizing ovarian cysts.
How PMOS May Present In Patients
This condition is difficult to diagnose because it manifests differently in each woman, with symptoms affecting multiple body systems and varying widely in severity.
Dark skin patches may be associated with PMOS
getty
From a reproductive perspective, symptoms may include irregular or absent periods, disrupted ovulation, excessive facial or body hair, hair thinning on the scalp, and infertility. Metabolically, patients may experience insulin resistance, weight gain, difficulty losing weight, and dark, velvety skin patches on the neck or armpits, alongside a significantly increased risk of prediabetes, type 2 diabetes, and cardiovascular disease. Other symptoms include severe acne, oily skin, persistent fatigue, anxiety, and depression, which often remain untreated due to the lack of connection to a unified hormonal issue.
For years, these symptoms were addressed as distinct problems by different specialists. PMOS encourages clinicians to consider them collectively.
Why Did The Change Happen Now?
“There is increased awareness of the multi-organ systems affected by this condition,” says Mahalingaiah. Both experts and patients recognized that the condition’s impact goes beyond the ovaries. “With the support of patient voices and advocacy teams, international teams of clinicians and researchers were motivated,” adds Mahalingaiah. She notes that the researchers and advocates took deliberate care in leading this global consensus process, acknowledging that such work requires time.
The aim is for the new name to influence how the condition is diagnosed, treated, funded, researched, and understood.
